NEW YORK (GenomeWeb News) – Response Genetics today said that it has signed definitive agreements with unnamed institutional investors for the sale of 932,805 shares of the firm's common stock through a registered direct offering.

The Los Angeles-based molecular diagnostics firm is selling the shares at $2.05 each, the stock's closing price on Thursday, and expects to raise gross proceeds of $1.9 million through the offering. It said it anticipates the offering will close on or around Sept. 25.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.